Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients (NCT05060991)
Impact of Immunosuppression Adjustment on the Immune Response to SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients (ADIVKT)
🩺 Plain-English Summary (8th-Grade Level)
Immunocompromised individuals, such as solid organ transplant (SOT) recipients are at high risk of COVID-19 associated complications and mortality. Retrospective studies so far have shown that a majority of SOT recipients did not develop appreciable anti-spike antibody response after a first, second, or even third dose of mRNA vaccine. Treatment with antimetabolites was associated with poor vaccine response. The goal of this study is 1) examine whether transient immunosuppression reduction improves the immune response to a third dose of SARS-CoV-2 mRNA vaccine in kidney transplant recipients and 2) to assess the safety of immunosuppression reduction before and after third dose SARS-CoV-2 mRNA vaccination.
Who can join: Review the eligibility criteria below.
Location: University of California, Davis — Sacramento, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of California, Davis — Sacramento, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in COVID-19
- COVID-19 and Cancer Consortium Registry — Nashville, Tennessee
- COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE) — Bethesda, Maryland
- Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans — Baltimore, Maryland
- Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings — Calgary, Alberta
- A Nasal Treatment for COVID-19 — Indianapolis, Indiana
Explore by condition: All COVID-19 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.